Title: Preoperative immune prognostic index predicts the prognosis and postoperative adjuvant
chemotherapy benefits of esophageal squamous cell carcinoma after minimally invasive
esophagectomy
Version: 2 Date: 23 Mar 2025
Reviewer's report:
This study categorized patients with esophageal squamous cell carcinoma (ESCC) who
underwent minimally invasive esophagectomy (MIE) into two groups: a low IPI group and a
high IPI group. It explored the relationship between these groups and their prognosis. The low
IPI group showed significantly better overall survival (OS) and disease-free survival (DFS) than
the high IPI group. Additionally, a subgroup analysis revealed that patients in the high IPI group
who received adjuvant chemotherapy (AC) had a better prognosis than those who did not receive
it. In other words, the authors suggest that patients with a high IPI will likely benefit from AC.
While the study presents interesting findings, the authors must address some issues.
1.
Analyses by a co-author specializing in statistics would improve the manuscript.
2.
What is the standard therapy for patients with locally advanced esophageal squamous cell
carcinoma (ESCC) in the author's hospital or country? Why were these patients excluded from
receiving preoperative neoadjuvant chemotherapy or chemoradiotherapy?
3.
The methods section should provide detailed postoperative chemotherapy protocols and explain
the treatment's indications.
4.
The methods section should outline the surgical procedures (McKeown and Ivor-Lewis).
5.
Overall Survival (OS) includes deaths from causes other than ESCC. To better understand the
relationship between IPI and the prognosis of ESCC patients, I request that the authors include
the analysis results for Disease-Specific Survival (DSS) and discuss the results.
Title: Preoperative immune prognostic index predicts the prognosis and postoperative adjuvant
chemotherapy benefits of esophageal squamous cell carcinoma after minimally invasive
esophagectomy
Version: 2 Date: 23 Mar 2025
Reviewer's report:
This study categorized patients with esophageal squamous cell carcinoma (ESCC) who
underwent minimally invasive esophagectomy (MIE) into two groups: a low IPI group and a
high IPI group. It explored the relationship between these groups and their prognosis. The low
IPI group showed significantly better overall survival (OS) and disease-free survival (DFS) than
the high IPI group. Additionally, a subgroup analysis revealed that patients in the high IPI group
who received adjuvant chemotherapy (AC) had a better prognosis than those who did not receive
it. In other words, the authors suggest that patients with a high IPI will likely benefit from AC.
While the study presents interesting findings, the authors must address some issues.
1.
Analyses by a co-author specializing in statistics would improve the manuscript.
2.
What is the standard therapy for patients with locally advanced esophageal squamous cell
carcinoma (ESCC) in the author's hospital or country? Why were these patients excluded from
receiving preoperative neoadjuvant chemotherapy or chemoradiotherapy?
3.
The methods section should provide detailed postoperative chemotherapy protocols and explain
the treatment's indications.
4.
The methods section should outline the surgical procedures (McKeown and Ivor-Lewis).
5.
Overall Survival (OS) includes deaths from causes other than ESCC. To better understand the
relationship between IPI and the prognosis of ESCC patients, I request that the authors include
the analysis results for Disease-Specific Survival (DSS) and discuss the results.
Please review this paper.
user
Title: Preoperative immune prognostic index predicts the prognosis and postoperative adjuvant
chemotherapy benefits of esophageal squamous cell carcinoma after minimally invasive
esophagectomy
Version: 2 Date: 23 Mar 2025
Reviewer's report:
This study categorized patients with esophageal squamous cell carcinoma (ESCC) who
underwent minimally invasive esophagectomy (MIE) into two groups: a low IPI group and a
high IPI group. It explored the relationship between these groups and their prognosis. The low
IPI group showed significantly better overall survival (OS) and disease-free survival (DFS) than
the high IPI group. Additionally, a subgroup analysis revealed that patients in the high IPI group
who received adjuvant chemotherapy (AC) had a better prognosis than those who did not receive
it. In other words, the authors suggest that patients with a high IPI will likely benefit from AC.
While the study presents interesting findings, the authors must address some issues.
1.
Analyses by a co-author specializing in statistics would improve the manuscript.
2.
What is the standard therapy for patients with locally advanced esophageal squamous cell
carcinoma (ESCC) in the author's hospital or country? Why were these patients excluded from
receiving preoperative neoadjuvant chemotherapy or chemoradiotherapy?
3.
The methods section should provide detailed postoperative chemotherapy protocols and explain
the treatment's indications.
4.
The methods section should outline the surgical procedures (McKeown and Ivor-Lewis).
5.
Overall Survival (OS) includes deaths from causes other than ESCC. To better understand the
relationship between IPI and the prognosis of ESCC patients, I request that the authors include
the analysis results for Disease-Specific Survival (DSS) and discuss the results.
assistant